SH2MAX Assay Panel offers a comprehensive screening solution to test for selectivity of molecules across 102 SH2 domain-containing proteins during all stages of drug discovery and development, from lead discovery & hit identification to lead optimization. SH2MAX is the largest human binding assay panel available on a single technology platform with no potential of compound interference in the assay readout.
SH2 domains play a central role in mediating protein-protein interactions by recognizing and binding phosphotyrosine residues on target proteins involved in the regulation and organization of cell signaling and macromolecular complex assembly in the cell. Overexpression or mutation of proteins that contain SH2 domains can lead to dysregulation of pathways involved in inflammation, autoimmunity and oncogenesis. The SH2MAX panel enables compound testing across a broad variety of wild-type and mutant SH2 domains in a single assay, which can be utilized in evaluating on-target and off-target effects and toxicity of molecules in any stage of the drug discovery process.
Panel Features & Benefits
- SH2scan assay principle developed using our gold standard KINOMEscan™ technology
- Covers 95 wild-type and 7 mutant SH2 domain-containing human protein targets
- Measures on-target and off-target effects and toxicity of molecules
- High-throughput, 384-well format allowing for library profiling
- High-quality reproducible data validated with internal reference controls
- Broad dynamic range: can detect compounds with Kds <100 pM >10 uM
- Rapid turnaround time
- Flexible – Standard and custom panels
For further information, please contact StudyDirectorsServicesSanDiego@discovery.eurofinsus.com
